Skip to main content

Table 2 Main results of pooled HRs in the meta-analysis

From: Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis

 

Study number

Sample size

OR/HR (95% CI)

P value

z

Heterogeneity

Publication bias (Eggers test)

I2 (%)

Ph

T-value

Pbias

Overall TNM stage (III/IV vs I/II)

70

11,901

2.19 (1.84–2.61)

P < 0.001

8.83

80.74

P < 0.001

2.40

0.018

Overall tumor differentiation (poor vs well/moderate)

59

9251

1.25 (1.01–1.55)

0.035

2.10

82.38

P < 0.001

1.84

0.07

Overall lymph node metastasis (Yes vs No)

76

13,172

1.76 (1.54–2.02)

0.00

8.23

73.57

P < 0.001

2.37

0.019

Overall OS

78

13,482

1.65 (1.54–1.77)

0.00

14.00

56.74

P < 0.001

3.70

P < 0.001

Overall DFS/RFS

18

1788

2.35 (1.90–2.89)

P < 0.001

7.96

46.93

0.015

1.63

0.12

Overall CSS/ DSS

8

1462

1.69 (1.33–2.15)

P < 0.001

4.32

49.04

0.056

1.00

0.35

CD44s

 TNM stage (III/IV vs I/II)

9

1331

2.74 (1.39–5.38)

0.003

2.93

83.96

P < 0.001

1.55

0.163

 Tumor differentiation (poor vs well/moderate)

9

1177

2.82 (1.50–5.30)

0.001

3.23

75.38

P < 0.001

0.71

0.49

 Lymph node metastasis (Yes vs No)

11

1638

1.64 (1.13–2.38)

0.009

2.62

56.83

0.010

1.65

0.13

 OS

11

1669

1.97 (1.55–2.50)

P < 0.001

5.61

54.99

0.014

1.62

0.13

 DFS/RFS

5

516

2.74 (1.80–4.17)

P < 0.001

4.69

42.23

0.14

–

–

 CSS/DSS

2

246

2.59 (1.32–5.06)

0.005

2.78

0.00

0.65

–

–

CD44V6

 TNM stage (III/IV vs I/II)

3

311

2.50 (1.22–5.14)

0.012

2.51

70.46

0.034

0.40

0.75

 Tumor differentiation (poor vs well/moderate)

5

684

0.93 (0.35–2.42)

0.88

− 0.14

86.80

P < 0.001

0.55

0.61

 Lymph node metastasis (Yes vs No)

5

684

2.26 (1.46–3.51)

P < 0.001

3.65

25.64

0.25

1.68

0.19

 OS

3

512

1.81 (1.29–2.53)

0.001

3.45

0.00

0.82

2.34

0.25

 CSS/DSS

3

295

3.29 (1.46–7.43)

0.004

2.87

61.63

0.10

–

–

CD44V9

 TNM stage (III/IV vs I/II)

2

637

5.39 (2.70–10.77)

P < 0.001

4.78

7.26

0.29

–

–

 Tumor differentiation (poor vs well/moderate)

3

559

0.98 (0.37–2.58)

0.98

− 0.025

84.72

0.001

14.65

0.043

 Lymph node metastasis (Yes vs No)

3

559

1.52 (0.91–2.52)

0.10

1.61

40.74

0.18

8.64

0.073

 OS

2

619

1.22 (0.96–1.54)

0.08

1.69

P < 0.001

0.74

–

–

 DFS/RFS

2

168

8.60 (1.70–43.57)

0.009

2.61

77.51

0.035

–

–

 CSS/DSS

2

246

1.67 (0.52–5.35)

0.38

0.86

0.00

0.48

–

–

CD133

 TNM stage (III/IV vs I/II)

11

1853

2.67 (1.84–3.89)

P < 0.001

5.16

54.01

0.016

0.25

0.80

 Tumor differentiation (poor vs well/moderate)

10

1677

0.87 (0.56–1.34)

0.53

− 0.62

70.18

P < 0.001

2.09

0.06

 Lymph node metastasis (Yes vs No)

11

1847

1.85 (1.22–2.79)

0.003

2.93

65.05

0.001

0.99

0.34

 OS

12

1939

1.74 (1.52–2.01)

P < 0.001

7.87

0.00

0.55

1.83

0.09

 DFS/RFS

3

343

2.59 (1.74–3.85)

P < 0.001

4.69

0.00

0.64

–

–

Sox-2

 TNM stage (III/IV vs I/II)

5

732

1.37 (0.65–2.90)

0.40

0.83

77.22

0.002

1.55

0.21

 Tumor differentiation (poor vs well/moderate)

2

119

1.21 (0.57–2.59)

0.60

0.51

23.37

0.25

–

–

 Lymph node metastasis (Yes vs No)

5

732

1.96 (1.40–2.73)

P < 0.001

3.99

0.00

0.42

0.84

0.46

 OS

6

804

1.73 (1.37–2.18)

P < 0.001

4.63

0.00

0.78

0.59

0.58

 DFS/RFS

1

69

1.31 (0.68–2.49)

0.41

0.82

0.00

1

–

–

Oct-4

 TNM stage (III/IV vs I/II)

6

1014

2.25 (1.09–4.66)

0.028

2.19

81.91

P < 0.001

0.79

0.47

 Tumor differentiation (poor vs well/moderate)

5

724

1.97 (0.86–4.50)

0.10

1.60

75.47

0.003

0.53

0.62

 Lymph node metastasis (Yes vs No)

6

1014

2.70 (1.09–6.68)

0.031

2.15

88.63

P < 0.001

1.15

0.31

 OS

7

1086

1.87 (1.48–2.35)

0.00

5.37

4.88

0.38

0.21

0.83

 DFS/RFS

2

114

2.18 (1.06–4.48)

0.023

2.13

11.13

0.28

–

–

ALDH1

 TNM stage (III/IV vs I/II)

4

760

3.66 (1.75–7.64)

0.001

3.45

74.19

0.009

1.31

0.31

 Tumor differentiation (poor vs well/moderate)

3

539

2.73 (0.43–17.19)

0.28

1.07

93.25

P < 0.001

4.6

0.13

 Lymph node metastasis (Yes vs No)

4

760

2.50 (0.96–6.45)

0.058

1.89

88.08

P < 0.001

0.09

0.93

 OS

5

851

1.65 (1.32–2.05)

P < 0.001

4.53

0.00

0.49

2.60

0.08

 DFS/RFS

2

307

1.49 (0.73–3.00)

0.27

1.10

56.39

0.13

–

–

LGR-5

 TNM stage (III/IV vs I/II)

5

1392

1.31 (0.46–3.74)

0.60

0.51

94.11

P < 0.001

0.58

0.6

 Tumor differentiation (poor vs well/moderate)

5

1423

1.04 (0.50–2.13)

0.91

0.10

87.79

P < 0.001

0.36

0.73

 Lymph node metastasis (Yes vs No)

6

1879

1.21 (0.70–2.09)

0.48

0.70

84.70

P < 0.001

0.01

0.98

 OS

5

1879

1.26 (0.97–1.63)

0.075

1.78

60.45

0.039

1.03

0.37

 CSS/DSS

1

456

1.02 (0.67–1.54)

0.90

0.11

0.00

1.00

–

–

Bmi-1

 TNM stage (III/IV vs I/II)

4

792

2.85 (1.04–7.81)

0.041

2.04

88.46

P < 0.001

1.07

0.36

 Tumor differentiation (poor vs well/moderate)

4

792

1.14 (0.70–1.85)

0.57

0.55

51.72

0.10

0.09

0.93

 Lymph node metastasis (Yes vs No)

5

1101

2.26 (1.19–4.26)

0.012

2.51

76.82

0.002

1.13

0.33

 OS

4

882

1.32 (0.77–2.27)

0.30

1.06

84.49

P < 0.001

1.57

0.25

 CSS/DSS

1

219

1.97 (1.35–2.87)

P < 0.001

3.52

0.00

1.00

–

–

Nanog

 TNM stage (III/IV vs I/II)

3

464

1.34 (0.78–2.31)

0.27

1.08

0.86

P < 0.001

0.49

0.70

 Tumor differentiation (poor vs well/moderate)

2

174

1.89 (0.06–55.82)

0.71

0.37

93.05

P < 0.001

–

–

 Lymph node metastasis (Yes vs No)

3

464

1.49 (0.73–3.02)

0.26

1.10

44.43

0.16

0.71

0.60

 OS

3

464

1.59 (0.68–3.77)

0.28

1.07

80.97

0.005

0.93

0.52

 DFS/RFS

1

69

2.09 (0.92–4.70)

0.075

1.77

0.00

1

–

–

CD24

 TNM stage (III/IV vs I/II)

5

905

1.31 (0.87–1.98)

0.18

1.32

43.46

0.13

0.91

0.42

  Tumor differentiation (poor vs well/moderate)

2

393

1.10 (0.18–6.46)

0.91

0.10

90.02

0.002

–

–

 Lymph node metastasis (Yes vs No)

5

905

1.40 (1.04–1.89)

0.026

2.23

20.17

0.28

0.46

0.67

 OS

5

905

1.73 (1.25–2.4)

0.001

4.10

35.46

0.18

2.71

0.07

 Gli-1

 TNM stage (III/IV vs I/II)

6

614

4.00 (1.58–10.13)

0.003

2.93

79.50

P < 0.001

1.07

0.34

 Tumor differentiation (poor vs well/moderate)

4

403

1.66 (0.81–3.40)

0.16

1.39

57.08

0.07

0.93

0.44

 Lymph node metastasis (Yes vs No)

5

493

3.04 (1.62–5.71)

0.001

3.47

51.59

0.08

0.60

0.59

 OS

8

776

1.75 (1.34–2.31)

0.00

4.06

7.79

0.37

0.14

0.88

 DFS/RFS

1

101

3.40 (1.30–8.7)

0.012

2.52

0.00

1

–

–

Shh

 TNM stage (III/IV vs I/II)

7

1096

2.19 (0.97–4.94)

0.056

1.90

86.32

P < 0.001

3.12

0.026

 Tumor differentiation (poor vs well/moderate)

5

687

1.02 (0.24–4.30)

0.97

0.037

90.31

P < 0.001

1.63

0.20

 Lymph node metastasis (Yes vs No)

7

1096

1.14 (0.54–2.39)

0.73

0.34

85.02

P < 0.001

0.48

0.64

  OS

7

1096

1.27 (0.78–2.05)

0.32

0.99

76.23

P < 0.001

0.72

0.49

 DFS/RFS

1

101

2.75 (1.15–6.54)

0.02

2.28

0.00

1

–

–

  1. Ph: The p-value of heterogeneity; P bias: The p-value of Egger test for assessing publication bias; OS: Overall survival; DFS: Disease-free survival; RFS: Relapse-free survival; CSS: Cancer-specific survival; DSS: Disease-specific survival
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us